Abstract
Introduction/ObjectivesNintedanib is a tyrosine kinase inhibitor demonstrated to slow the rate of progression of fibrotic interstitial lung diseases (ILD). Originally available solely for the treatment of idiopathic pulmonary fibrosis (IPF),...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have